When do biologic drug patents expire and when will biosimilars launch?

Patent 8,778,359 Landscape: What Is Claimed, How Broad It Is, and Which US Anthrax Vaccine Patents Block Competitors

US Patent 8,778,359 covers an anthrax protective antigen (PA) subunit vaccine with a specific stability/solubility formulation architecture: purified Bacillus anthracis protective antigen protein, an “alanine formulation buffer” with defined concentration and pH windows, and a pharmaceutically acceptable adjuvant. The independent claim is formulation-defined, not platform-defined. The dependent claims narrow to (i) alanine buffer composition (including a named “about 220 mM alanine, about 25 mM sodium phosphate, about 0.01% polysorbate 80” embodiment), (ii) allowable adjuvant set (Alhydrogel, CpG/ISS, calcium phosphate), (iii) optional PA production from an asporogenic B. anthracis strain, and (iv) a specific PA sequence window (amino acids 30-735 of SEQ ID NO:1) and dosing floor. The most practical competitive risk is not “PA as an antigen,” which is crowded. It is the ability to match the specific alanine-buffer stability formulation plus adjuvant package while still being manufacturable and FDA-viable.

What does US Patent 8,778,359 claim for an anthrax protective antigen (PA) subunit vaccine?

Direct answer: The patent claims a stable, liquid anthrax PA vaccine built around three elements: (a) purified PA protein, (b) an alanine formulation buffer, and (c) a pharmaceutically acceptable adjuvant. Dependent claims fix alanine concentration, an example buffer recipe, pH, optional co-amino acids, adjuvant species, dosing, PA source strain, PA sequence region, and delivery format.

Claim 1 (independent): the formulation triad

Claim 1 requires all of the following in one vaccine composition:

Purified Bacillus anthracis protective antigen protein
Alanine formulation buffer
Pharmaceutically acceptable adjuvant

This is a classic composition-of-matter framed around stability and compatibility. The PA antigen is necessary but not sufficient; the novelty is positioned in the buffer system combined with an adjuvant.

Key dependent claim narrowing that matters for design-around

Alanine concentration range (Claim 2): about 50 to 500 mM alanine
Specific buffer recipe (Claim 3): about 220 mM alanine, about 25 mM sodium phosphate, about 0.01% polysorbate 80
Optional co-solutes (Claim 4): buffer further comprises glycine and/or proline
pH range (Claim 5): about pH 6.2 to 8.0
Adjuvant list (Claim 6): selected from Alhydrogel, CpG, immunostimulatory sequence (ISS), calcium phosphate
Alhydrogel aluminum dose (Claim 8): about 750 µg aluminum
PA production source (Claims 9-10): PA produced from asporogenic B. anthracis; specifically ASterne-1(pPA102)CR4
PA sequence window (Claims 11-12): PA comprises amino acids 30-735 of SEQ ID NO:1; also “comprises SEQ ID NO:1”
PA dose minimum (Claim 13): at least about 25 µg PA
PA + aluminum minimum (Claim 14): at least about 25 µg PA and about 750 µg aluminum
Dosage form (Claim 19): liquid solution or suspension

Practical read: If a competitor uses a different buffer system (non-alanine), a different pH window, or an adjuvant outside the listed set, literal infringement risk drops sharply. If they stay inside the alanine buffer family but alter amino acid complements, polysorbate concentration, phosphate level, or aluminum dosing, infringement turns on claim construction for “about” and whether their product composition falls within the claimed numerical bounds.

How broad is the claim coverage of US 8,778,359 across buffer, pH, adjuvant, and dosing?

Direct answer: Coverage is broad on alanine concentration (50–500 mM) and pH (6.2–8.0) but narrow on at least two axes: (i) the requirement that the buffer is an “alanine formulation buffer” (not just “any amino acid”), and (ii) the adjuvant category selection in the dependent claims.

Breadth map (what is wide vs tight)

Claim element	Claim 1 breadth	Dependent claims tightening	Competitor design implication
Alanine buffer	Required but not quantified in Claim 1	Claim 2: 50–500 mM; Claim 3: specific formulation; Claim 5: pH 6.2–8.0; Claim 4 adds glycine/proline	Switching to non-alanine buffers (citrate, histidine, tris, acetate) is the strongest off-ramp.
PA antigen	Purified PA protein required	Claim 11: amino acids 30–735 of SEQ ID NO:1	Using a different PA variant/construct sequence can avoid alignment to SEQ ID NO:1.
Adjuvant	Required but “pharmaceutically acceptable” in Claim 1	Claim 6 restricts adjuvant set; Claim 7-8 narrow to Alhydrogel with ~750 µg aluminum	If the commercial comparator uses a different adjuvant chemistry not listed, dependent claims may be avoided.
Dosing	Not fixed in Claim 1	Claim 13-14 set minimum PA and PA+aluminum	Lower PA dose or different aluminum dose can avoid dependent claim hits.
Liquid format	Not in Claim 1	Claim 19 requires solution/suspension	If a competitor uses a different form factor (e.g., lyophilized with reconstitution), Claim 19 may not read, though Claim 1 may still apply.
PA source strain	Not in Claim 1	Claims 9-10 add asporogenic strain and a specific strain	Source strain requirements rarely limit product because PA purification can occur from many sources, but depending on claim construction, the manufacture history may matter.

What formulations are protected by US 8,778,359 (and what are the main infringement pathways)?

Direct answer: The patent protects a PA vaccine in an alanine-stability buffer across a defined alanine and pH envelope, with allowable adjuvants including Alhydrogel and nucleic-acid stimulation systems (CpG/ISS) and calcium phosphate. The most direct infringement pathway is making, using, selling, offering for sale, or importing a liquid PA vaccine that contains the claimed alanine buffer system plus one of the adjuvant categories.

Most relevant literal infringement route (composition match)

A product matches Claim 1 if it has:

purified B. anthracis PA protein;
alanine formulation buffer; and
pharmaceutically acceptable adjuvant.

It matches key dependent claims if it also has the specific quantified buffer, pH, adjuvant selection, and dosing thresholds.

Potential non-literal routes (doctrinally)

Even if a competitor avoids exact numerical values, “about” tolerances create litigation risk if the product’s values are close enough to be argued as equivalent. If a competitor swaps adjuvant chemistry, they may still face allegations under doctrine-of-equivalents theories tied to “pharmaceutically acceptable adjuvant” in Claim 1 (less constrained than Claim 6).

When does US 8,778,359 expire and what exclusivity windows could still matter?

Direct answer: The claim set you provided is US Patent 8,778,359. However, no filing date, application publication number, or priority details were provided in the prompt. Without those, a complete, accurate exclusivity timeline (including patent term adjustment, terminal disclaimer effect, and any BLA/IND market exclusivity interactions) cannot be produced from the information given here.

Which companies are challenging anthrax PA vaccine patents with Paragraph IV or non-PIV strategies?

Direct answer: A compliant list of entities challenging US 8,778,359 specifically (Paragraph IV settlements, district court dockets, and generic or biosimilar pathways) cannot be produced from the provided prompt. The claims alone do not identify the assignee, patent family, or litigation docket needed to build an accurate “who is challenging whom” map.

What is the Orange Book status of US 8,778,359 and how does it affect generic entry risk?

Direct answer: Orange Book status is tied to FDA-approved listed products and patents linked to specific NDA/BLA references. The prompt provides no FDA product identifier(s) tied to this patent, no Orange Book listing number, and no reference product. A complete Orange Book mapping and generic entry risk assessment cannot be generated from the provided information.

How strong is the patent estate for alanine-buffered anthrax PA vaccines: is this an isolated claim or a family block?

Direct answer: Patent estate strength depends on the full family (continuations/divisionals), prosecution history, related method-of-manufacture or dosing patents, and whether other members claim adjacent formulation or process features. The prompt provides only the claims of one US patent number and does not provide the broader family or related US continuations needed for an estate-level strength assessment.

What other patent claim themes commonly overlap with US 8,778,359 in anthrax vaccine IP (formulation, antigen variants, and methods)?

Direct answer: The landscape for anthrax PA vaccines typically includes overlapping IP themes: antigen sequence/construct claims (PA domains, truncations, mutants), formulation and stabilization claims (buffers, surfactants like polysorbate, pH windows, tonicity agents, filtration/lyophilization stability), adjuvant composition and dose claims (alum types and microgram aluminum per dose, CpG/ISS oligonucleotide sequences, calcium phosphate precipitation), and methods of use (inhalation anthrax prophylaxis/treatment, immunogenicity methods).

How those themes intersect with this patent

Antigen identity claims (Claims 11-12) narrow to defined PA sequence regions. This can create “stacked” infringement risk when other patents protect other PA constructs.
Stability formulation claims (Claims 2-5, 19) are where competitors often shift approaches to clear IP.
Adjuvant and dosing (Claims 6-8, 14) often represent a second design axis because commercial products have historically used alum-based adjuvants.

How does US 8,778,359 compare with generic substitutes of PA vaccines: what design-around levers are most plausible?

Direct answer: The main design-around levers suggested by the claim language are (i) change the buffer system away from an “alanine formulation buffer,” (ii) move outside the claimed alanine concentration and/or pH envelope, (iii) avoid the dependent adjuvant selections and aluminum dosing thresholds, and (iv) use a PA construct not falling within the claimed SEQ ID NO:1 region.

Design-around levers extracted from the claims

Buffer swap: replace alanine buffer with other stabilization buffers (the claims do not cover non-alanine systems in Claim 1 as written).
Numerical deviation: avoid alanine 50–500 mM, or avoid the specific recipe (220 mM alanine/25 mM phosphate/0.01% polysorbate 80), or shift pH outside 6.2–8.0.
Adjuvant route: use adjuvant types not included in Claim 6 (dependent claims), and/or avoid alum content approximating 750 µg.
Antigen construct: use a PA version not comprising amino acids 30–735 of SEQ ID NO:1.
Dosing: avoid the minimum PA dose floor (Claim 13) and aluminum amount floor (Claim 14).

What method-of-use claims are included, and do they expand infringement beyond the composition?

Direct answer: The patent includes method-of-use claims that are tied to administering the claimed vaccine to prevent or treat anthrax (including inhalation anthrax) and to induce an immune response.

Method claims

Claim 15: preventing or treating an anthrax disease
Claim 16: inhalation anthrax
Claim 17-18: inducing an immune response and vaccinating against anthrax by administering the vaccine
Infringement consequence: Even if a product design avoids some formulation dependent claims, if it still falls within Claim 1’s composition boundaries, administering it can implicate method claims.

Key Takeaways

Claim 1 is the anchor: stable anthrax PA vaccine defined by the combination of purified PA, an “alanine formulation buffer,” and a pharmaceutically acceptable adjuvant.
Main risk concentration is formulation matching: the dependent claims quantify alanine concentration (50–500 mM), define a specific buffer recipe (220 mM alanine/25 mM phosphate/0.01% polysorbate 80), and constrain pH (6.2–8.0).
Adjuvant and dosing add additional tripwires: dependent claims cover Alhydrogel, CpG/ISS, and calcium phosphate, with specific aluminum dose concepts around 750 µg.
Antigen identity narrowing exists: amino acids 30–735 of SEQ ID NO:1 and “comprises SEQ ID NO:1” can matter if competitors shift PA constructs.
Method-of-use claims expand exposure: administration-based claims rely on the vaccine composition meeting Claim 1.

FAQs

1. If a competitor uses purified PA but a non-alanine buffer, does US 8,778,359 still read?
As written, Claim 1 requires an “alanine formulation buffer,” so a non-alanine buffer is the most direct categorical design-around.

2. How risky is altering polysorbate 80 within the claimed recipe?
Risk depends on whether the formulation is argued to fall within “about 0.01%” in Claim 3, and whether it still meets Claim 2 and Claim 5 constraints.

3. Can a competitor avoid dependent claims by using an adjuvant outside the Claim 6 list?
It can reduce exposure to dependent claims 6-8, but Claim 1 still requires an adjuvant and uses broader language in “pharmaceutically acceptable adjuvant.”

4. Does the patent protect lyophilized products or only liquid suspensions?
Claim 19 explicitly covers liquid solution or suspension, but Claim 1 does not expressly restrict format.

5. Do the asporogenic source strain limitations (ASterne-1(pPA102)CR4) affect product infringement?
Those limitations are in dependent claims 9-10. If a product is not shown to use the claimed source strain and the claim construction treats source requirements as product-limiting, infringement may narrow to the formulation-level claims.

References (APA)

US Patent 8,778,359.

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Emergent Biodefense Operations Lansing Llc	BIOTHRAX	anthrax vaccine adsorbed	Injection	103821	November 12, 1998	8,778,359	2029-07-30
Emergent Product Development Gaithersburg, Inc.	CYFENDUS	anthrax vaccine adsorbed, adjuvanted	Injection	125761	July 20, 2023	8,778,359	2029-07-30
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2010053610	⤷ Start Trial
United States of America	2015023998	⤷ Start Trial
United States of America	2011229507	⤷ Start Trial
European Patent Office	2320945	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration

Patent: 8,778,359

Summary for Patent: 8,778,359